Abstract
Introduction: Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs. International guidelines recommend the use of long-acting bronchodilators (β2 agonists and anti-cholinergics/muscarinics), inhaled steroids and associations between these drugs in the maintenance treatment of moderate-to-severe COPD. Area covered: Vilanterol trifenate is a new once-daily highly selective β2-agonist available in USA and Europe in association with umeclidinium bromide (a long-acting anti-muscarnic agent) and fluticasone furoate (an inhaled corticosteroid) for the once-daily maintenance treatment of COPD. Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. Expert commentary: These new once-daily formulations have the potential to improve compliance to long-term inhaled therapy. This paper will review the clinical and experimental data regarding vilanterol use in the regular treatment of COPD as well as provide a critical discussion of possible future treatment settings.
Original language | English |
---|---|
Pages (from-to) | 719-731 |
Number of pages | 13 |
Journal | Expert Review of Respiratory Medicine |
Volume | 10 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2 Jul 2016 |
Externally published | Yes |
Keywords
- COPD treatment
- LABA
- LAMA
- Vilanterol trifenate
- fluticasone furoate
- umeclidinium bromide